Literature DB >> 20430957

Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity.

Christian Wichmann1, Yvonne Becker, Linping Chen-Wichmann, Vitali Vogel, Anna Vojtkova, Julia Herglotz, Sandra Moore, Joachim Koch, Jörn Lausen, Werner Mäntele, Holger Gohlke, Manuel Grez.   

Abstract

RUNX1/ETO, the fusion protein resulting from the chromosomal translocation t(8;21), is one of the most frequent translocation products in acute myeloid leukemia. Several in vitro and in vivo studies have shown that the homo-tetramerization domain of ETO, the nervy homology region 2 (NHR2), is essential for RUNX1/ETO oncogenic activity. We analyzed the energetic contribution of individual amino acids within the NHR2 to RUNX1/ETO dimer-tetramer transition and found a clustered area of 5 distinct amino acids with strong contribution to the stability of tetramers. Substitution of these amino acids abolishes tetramer formation without affecting dimer formation. Similar to RUNX1/ETO monomers, dimers failed to bind efficiently to DNA and to alter expression of RUNX1-dependent genes. RUNX1/ETO dimers do not block myeloid differentiation, are unable to enhance the self-renewal capacity of hematopoietic progenitors, and fail to induce leukemia in a murine transplantation model. Our data reveal the existence of an essential structural motif (hot spot) at the NHR2 dimer-tetramer interface, suitable for a molecular intervention in t(8;21) leukemias.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20430957     DOI: 10.1182/blood-2009-10-248047

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization.

Authors:  Julia Schanda; Chun-Wei Lee; Katharina Wohlan; Uta Müller-Kuller; Hana Kunkel; Isabell Quagliano-Lo Coco; Stefan Stein; Alexander Metz; Joachim Koch; Jörn Lausen; Uwe Platzbecker; Hind Medyouf; Holger Gohlke; Michael Heuser; Matthias Eder; Manuel Grez; Michaela Scherr; Christian Wichmann
Journal:  Haematologica       Date:  2017-02-02       Impact factor: 9.941

2.  Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion.

Authors:  Linping Chen-Wichmann; Marina Shvartsman; Caro Preiss; Colin Hockings; Roland Windisch; Enric Redondo Monte; Georg Leubolt; Karsten Spiekermann; Jörn Lausen; Christian Brendel; Manuel Grez; Philipp A Greif; Christian Wichmann
Journal:  Oncogene       Date:  2018-08-09       Impact factor: 9.867

3.  GFI1 is required for RUNX1/ETO positive acute myeloid leukemia.

Authors:  Anna E Marneth; Lacramioara Botezatu; Judith M Hönes; Jimmy C L Israël; Judith Schütte; Lothar Vassen; Robert F Lams; Saskia M Bergevoet; Laura Groothuis; Amit Mandoli; Joost H A Martens; Gerwin Huls; Joop H Jansen; Ulrich Dührsen; Tobias Berg; Tarik Möröy; Christian Wichmann; Mia-Chia Lo; Dong-Er Zhang; Bert A van der Reijden; Cyrus Khandanpour
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941

Review 4.  RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making.

Authors:  James K Mangan; Nancy A Speck
Journal:  Crit Rev Oncog       Date:  2011

5.  Complex long-distance effects of mutations that confer linezolid resistance in the large ribosomal subunit.

Authors:  Simone Fulle; Jagmohan S Saini; Nadine Homeyer; Holger Gohlke
Journal:  Nucleic Acids Res       Date:  2015-07-21       Impact factor: 16.971

6.  Defined Human Leukemic CD34+ Liquid Cultures to Study HDAC/Transcriptional Repressor Complexes.

Authors:  Roland Windisch; Sophie Kreissig; Christian Wichmann
Journal:  Methods Mol Biol       Date:  2023

7.  ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.

Authors:  Joost H A Martens; Amit Mandoli; Femke Simmer; Bart-Jan Wierenga; Sadia Saeed; Abhishek A Singh; Lucia Altucci; Edo Vellenga; Hendrik G Stunnenberg
Journal:  Blood       Date:  2012-09-14       Impact factor: 22.113

8.  Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers.

Authors:  Alexandre Fagnan; Frederik Otzen Bagger; Maria-Riera Piqué-Borràs; Cathy Ignacimouttou; Alexis Caulier; Cécile K Lopez; Elie Robert; Benjamin Uzan; Véronique Gelsi-Boyer; Zakia Aid; Cécile Thirant; Ute Moll; Samantha Tauchmann; Amina Kurtovic-Kozaric; Jaroslaw Maciejewski; Christine Dierks; Orietta Spinelli; Silvia Salmoiraghi; Thomas Pabst; Kazuya Shimoda; Virginie Deleuze; Hélène Lapillonne; Connor Sweeney; Véronique De Mas; Betty Leite; Zahra Kadri; Sébastien Malinge; Stéphane de Botton; Jean-Baptiste Micol; Benjamin Kile; Catherine L Carmichael; Ilaria Iacobucci; Charles G Mullighan; Martin Carroll; Peter Valent; Olivier A Bernard; Eric Delabesse; Paresh Vyas; Daniel Birnbaum; Eduardo Anguita; Loïc Garçon; Eric Soler; Juerg Schwaller; Thomas Mercher
Journal:  Blood       Date:  2020-08-06       Impact factor: 25.476

9.  Pontin is a critical regulator for AML1-ETO-induced leukemia.

Authors:  O Breig; S Bras; N Martinez Soria; D Osman; O Heidenreich; M Haenlin; L Waltzer
Journal:  Leukemia       Date:  2013-12-17       Impact factor: 11.528

10.  Tetramerization reinforces the dimer interface of MnSOD.

Authors:  Yuewei Sheng; Armando Durazo; Mikhail Schumacher; Edith Butler Gralla; Duilio Cascio; Diane E Cabelli; Joan Selverstone Valentine
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.